| Haller, Michael J |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/24 | 05/25 | | |
NCT03961854: Lactobacillus Johnsonii in Children and Adolescents With T1D |
|
|
| Recruiting | 2 | 57 | US | L. johnsonii Probiotic, Placebo Capsule | University of Florida, Juvenile Diabetes Research Foundation | Type 1 Diabetes (T1D) | 03/26 | 03/26 | | |
NCT03961347: Lactobacillus Johnsonii Supplementation in Adults With T1D |
|
|
| Recruiting | 2 | 57 | US | L. johnsonii Probiotic, Placebo Capsule | University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes (T1D) | 06/26 | 06/26 | | |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes |
|
|
| Recruiting | 2 | 74 | US, RoW | Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) | Type 1 Diabetes Mellitus | 10/27 | 10/29 | | |
| Active, not recruiting | 2 | 101 | US, RoW | Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 12/28 | 12/29 | | |
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 |
|
|
| Completed | 1 | 47 | US | NNC0361-0041, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S | Type I Diabetes | 08/23 | 04/24 | | |
| Completed | N/A | 32796 | US | ECHO Tele-Education | University of Florida | Type 1 Diabetes, Type 2 Diabetes | 06/22 | 12/23 | | |
| Completed | N/A | 246 | US | MRI, US, and blood samples, Magnetic Resonance Imaging, Ultrasounography | University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diabetes Action Research and Education Foundation | Type 1 Diabetes | 04/23 | 04/23 | | |
NCT06348160: iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes |
|
|
| Recruiting | N/A | 192 | US | iHERO Toolkit Resource | Julia Blanchette, The Leona M. and Harry B. Helmsley Charitable Trust | Type 1 Diabetes | 03/26 | 03/26 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 75000 | Europe, Canada, US, RoW | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR) | Diabetes Mellitus, Type 1 | 07/25 | 07/25 | | |
| Jones, Thomas I |
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) |
|
|
| Completed | 4 | 152 | US | Tirzepatide, LY3298176 | Eli Lilly and Company | Type 2 Diabetes, Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes |
|
|
| Recruiting | 2 | 186 | Canada, US | Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg | Zucara Therapeutics Inc. | Type 1 Diabetes Mellitus with Hypoglycemia | 06/25 | 07/25 | | |
| Recruiting | N/A | 250 | Europe, US | reSept ASD Occluder | atHeart Medical | Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities | 12/26 | 12/30 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Bode, Bruce |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
| Completed | 2 | 265 | Europe, Canada, US, RoW | INV-202, None applicable, Placebo | Inversago Pharma Inc., Worldwide Clinical Trials | Diabetic Kidney Disease | 08/24 | 09/24 | | |
| Active, not recruiting | 2 | 140 | Europe, US, RoW | Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo | Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a. | Recent Onset type1 Diabetes | 04/24 | 04/26 | | |
| Recruiting | N/A | 20 | US | Experimental prospective single arm evaluating the Medtronic Duo Extended Set, Medtronic DUO Extended Set with 670G Pump Therapy | Atlanta Diabetes Associates, Medtronic | Diabetes Mellitus, Type 1 | 10/21 | 11/21 | | |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT05908448: The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | N/A | 134 | US | 13 CGM (continuous glucose monitor) | Sinocare, Atlanta Diabetes Associates | T1DM - Type 1 Diabetes Mellitus | 10/24 | 11/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® |
|
|
| Completed | N/A | 240 | Canada, US, RoW | MiniMed 780G System | Medtronic Diabetes | Type 1 Diabetes | 06/24 | 06/24 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 925 | US | Blood glucose meter, Eversense CGM System | Senseonics, Inc. | Diabetes | 03/26 | 03/26 | | |
| Laffel, Lori |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/24 | 05/25 | | |
NCT06362265: A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 1 | 22 | US | LY3209590 | Eli Lilly and Company | Type 2 Diabetes Mellitus | 11/26 | 11/26 | | |
NCT05403502: Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes |
|
|
| Completed | N/A | 183 | US | t:slim X2 insulin pump with Control-IQ technology 1.5 | Tandem Diabetes Care, Inc., Eli Lilly and Company, Jaeb Center for Health Research | Type 1 Diabetes | 08/23 | 08/23 | | |
NCT05683392: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes |
|
|
| Completed | N/A | 72 | US | t:slim X2 insulin pump with Control-IQ technology 2.0 | Tandem Diabetes Care, Inc. | Type 1 Diabetes | 12/23 | 12/23 | | |
| Active, not recruiting | N/A | 200 | Europe, US | Omnipod 5 System | Insulet Corporation | Type 1 Diabetes | 09/23 | 01/25 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT05413239: Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D) |
|
|
| Active, not recruiting | N/A | 191 | US | Psychoeducation to reduce diabetes distress and improve glycemic outcomes | Joslin Diabetes Center, Stanford University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes | 11/24 | 11/25 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Blevins, Thomas C |
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) |
|
|
| Completed | 4 | 152 | US | Tirzepatide, LY3298176 | Eli Lilly and Company | Type 2 Diabetes, Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections |
|
|
| Completed | 3 | 730 | Europe, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar | Eli Lilly and Company, Eli Lilly and Company | Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | 02/24 | 02/24 | | |
| Active, not recruiting | 3 | 75 | Europe, Canada, Japan, US, RoW | Plozasiran, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Familial Chylomicronemia | 04/24 | 04/26 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes |
|
|
| Completed | N/A | 319 | Canada, US | t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM) | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type 2 Diabetes Treated With Insulin | 09/24 | 09/24 | | |
| Harrison, Lindsay B |
| Terminated | 2b | 98 | Europe, Canada, US, RoW | EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo | Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc. | Non-Alcoholic Steatohepatitis | 10/21 | 11/21 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
| Ozer, Kerem |
MATILDA, NCT05632276: A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds |
|
|
| Completed | N/A | 54 | US | ConvaFoam, ConvaFoam Silicone, ConvaFoam Border, ConvaFoam Non Adhesive | ConvaTec Inc. | Surgical Wound, Trauma-related Wound | 03/24 | 03/24 | | |
NCT05805046: Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System |
|
|
| Withdrawn | N/A | 59 | US | Negative Pressure Wound Therapy System, Avelle™ Negative Pressure Wound Therapy System | ConvaTec Inc. | Surgical Wound, Recent, Surgical Wound Leak, Dehiscence Wound, Trauma-related Wound | 10/23 | 10/23 | | |
| Casaubon, Luis |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Garcia, Jose Luis |
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) |
|
|
| Completed | 3 | 1453 | US | Placebo, Montelukast | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 07/23 | 01/24 | | |
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications |
|
|
| Completed | 3 | 10956 | US | Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 04/24 | 04/24 | | |
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) |
|
|
| Completed | 3 | 3214 | US | Placebo, Metformin | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 06/24 | 11/24 | | |
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma |
|
|
| Recruiting | 3 | 412 | Europe, Canada, US, RoW | Salbutamol HFA-134a, Salbutamol HFA-152a | GlaxoSmithKline | Asthma | 04/25 | 04/25 | | |
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
GRIT, NCT04867317: Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) |
|
|
| Recruiting | 3 | 172 | US | Somatropin, Placebo | VA Office of Research and Development | Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury | 03/26 | 03/28 | | |
| Completed | 2 | 203 | Europe, US, RoW | Olorofim, F901318 | F2G Biotech GmbH, Iqvia Pty Ltd | Invasive Fungal Infections | 02/23 | 02/23 | | |
NCT05312567: FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms |
|
|
| Completed | 2 | 105 | US | FP-101 | Fervent Pharmaceuticals, ICON plc | Vasomotor Symptoms, Menopause | 04/23 | 07/23 | | |
| Completed | 2 | 39 | Europe, US, RoW | RGH-706, Placebo | Gedeon Richter Plc., Gedeon Richter Plc, Chemical Works of Gedeon Richter Plc | Prader-Willi Syndrome | 04/24 | 04/24 | | |
| Recruiting | 2 | 20 | US | Recombinant human growth hormone, Somatropin, Genotropin, Humatrope, Norditropin | Baylor College of Medicine, United States Department of Defense | Gulf War Syndrome, Adult Growth Hormone Deficiency | 05/25 | 09/25 | | |
TEMEC, NCT04301765: Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency |
|
|
| Recruiting | 2 | 230 | US | testosterone 1.62% gel, placebo gel | Seattle Institute for Biomedical and Clinical Research | Hypogonadism, Male, Cancer, Fatigue | 01/26 | 01/26 | | |
NCT04049331: Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone |
|
|
| Recruiting | 2 | 240 | US | Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], study drug, placebo | Seattle Institute for Biomedical and Clinical Research | Hypogonadism, Male, Fatigue Syndrome, Chronic | 01/26 | 01/26 | | |
| Terminated | 1/2 | 102 | Europe, US | Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi | Epizyme, Inc. | Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | 11/24 | 11/24 | | |
|
|
| Terminated | N/A | 32 | Europe | dPR and FFR | Opsens, Inc. | Aortic Stenosis | 03/23 | 04/23 | | |
NCT03867357: Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia |
|
|
| Completed | N/A | 60 | US | GnRH agonist, Zoladex, Goserelin | Seattle Institute for Biomedical and Clinical Research, United States Department of Defense, University of Washington | Metastatic Prostate Cancer, Androgen Deprivation Therapy | 09/23 | 09/23 | | |
Mavericks, NCT05758545: Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 450 | US | COMS One device, Concurrent Optical and Magnetic Stimulation, Sham device | Piomic Medical, NAMSA | Diabetic Foot Ulcer | 06/27 | 06/27 | | |
NCT04364256: Muscle Stimulation for Physical Function During Stem Cell Transplant |
|
|
| Active, not recruiting | N/A | 46 | US | RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA), NMES, e-stim | VA Office of Research and Development | Autologous Hematopoietic Stem Cell Transplant | 12/25 | 05/26 | | |
| Reed, John H |
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) |
|
|
| Completed | 4 | 152 | US | Tirzepatide, LY3298176 | Eli Lilly and Company | Type 2 Diabetes, Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
| Completed | 2 | 265 | Europe, Canada, US, RoW | INV-202, None applicable, Placebo | Inversago Pharma Inc., Worldwide Clinical Trials | Diabetic Kidney Disease | 08/24 | 09/24 | | |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT02748018: Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home |
|
|
| Active, not recruiting | N/A | 280 | Europe, Canada, US, RoW | 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy | Medtronic Diabetes | Type 1 Diabetes | 03/25 | 06/25 | | |
NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes |
|
|
| Completed | N/A | 260 | US | SteadiSet Extended Wear Infusion Set | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type1diabetes | 12/24 | 12/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® |
|
|
| Completed | N/A | 240 | Canada, US, RoW | MiniMed 780G System | Medtronic Diabetes | Type 1 Diabetes | 06/24 | 06/24 | | |
NCT06452914: Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks |
|
|
| Not yet recruiting | N/A | 80 | NA | Semiconductor Embedded Therapeutic Socks, Placebo Socks | Endocrine Research Solutions, INCREDIWEAR HOLDINGS, INC. | Diabetic Neuropathy | 06/25 | 06/25 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Tapia, Jessica |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT02748018: Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home |
|
|
| Active, not recruiting | N/A | 280 | Europe, Canada, US, RoW | 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy | Medtronic Diabetes | Type 1 Diabetes | 03/25 | 06/25 | | |
NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes |
|
|
| Completed | N/A | 260 | US | SteadiSet Extended Wear Infusion Set | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type1diabetes | 12/24 | 12/24 | | |
